Breaking News

Xcell Biosciences Plans $27.5M Series B Financing

Aims to further advance the production of Xcellbio’s new cell manufacturing platform, the KALI Cell Foundry.

Author Image

By: Charlie Sternberg

Associate Editor

Xcell Biosciences Inc., a developer of technologies and platforms designed to further the research, development, and manufacturing of cell and gene therapies, has announced $27.5 million in Series B financing led by Casdin Capital.   Also participating in this financing are new investors Dynamk Capital, Formic Ventures, and Labcorp, as well as existing investors HBM Genomics and Viking Global Investors. In connection with the financing, Shaun Rodriguez, PhD, director of Life Science Research a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters